Perspectives on Optimizing Immunotherapy in Advanced BCC and CSCC

Program Overview

This activity uniquely features 2 experts in the management of advanced nonmelanoma skin cancer (NMSC) and also, 2 immunotherapy-treated patients – one with BCC and the other with CSCC – in an interactive panel discussion that offers privileged insights into the latest clinical trial data.

Credit Expired

Target Audience

This educational activity is designed to meet the needs of medical oncology physicians, dermatology physicians, and other clinicians involved in the management of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Integrate immunotherapy in the management of patients with advanced basal cell carcinoma (BCC) based on the latest clinical trial data
Select appropriate immunotherapy for advanced cutaneous squamous cell carcinoma (CSCC) based on current safety and efficacy data

Activity Faculty

Karl D. Lewis, MD

Professor, Medicine
Division of Medical Oncology
Cutaneous Oncology Program
University of Colorado
Aurora, CO

Ahmad Tarhini, MD, PhD

Senior Member, Cutaneous Oncology and Immunology
Director, Cutaneous Clinical and Translational Research
H. Lee Moffitt Cancer Center and Research Institute
Professor, Oncologic Sciences
University of South Florida Morsani College of Medicine
Tampa, FL